Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aranesp Versus Procrit: Amgen Will Submit Comparative Data to CMS

Executive Summary

Amgen expects to present data demonstrating that front-loaded doses of the anemia agent Aranesp have advantages over standard doses of Johnson & Johnson's Procrit in cancer patients by year-end
Advertisement

Related Content

Aranesp Fallout: Managed Care May Follow CMS In “Functional Equivalence”
Aranesp Fallout: Managed Care May Follow CMS In “Functional Equivalence”
“Value-Based” Reimbursement: Is Aranesp Decision Future Medicare Model?
“Value-Based” Reimbursement: Is Aranesp Decision Future Medicare Model?
Nexium Prescribers Should Be “Embarrassed,” CMS’ Scully Tells AMA
Nexium Prescribers Should Be “Embarrassed,” CMS’ Scully Tells AMA
Amgen Discounting Aranesp After Medicare Reimbursement Cut
J&J Eprex “Best Handling Practices” Program Aims To Reduce PRCA Cases
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
Aranesp, Procrit Are “Functionally Equivalent,” CMS Says In Final OPPS Rule
Advertisement
UsernamePublicRestriction

Register

PS041337

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel